Vaccines such as Afluria®, Fluzone® and Fluvirin® offer first-line defense for patients of all ages.
Now more than ever, increasing flu vaccination rates is a major public health goal. Afluria®, Fluzone® and Fluvirin® influenza virus vaccines are essential in the fight against influenza and can help protect you and your patients this coming flu season. Learning more about these valuable flu vaccines can help you educate your patients, plan an effective flu-shot clinic and boost vaccination rates in your practice and community.
Afluria is an influenza vaccine that is available in thimerosal-free, prefilled syringes and multi-dose vials containing thimerosal as a preservative. Indicated for adults 18 years and older, Afluria received FDA approval just in time for the 2008-2009 flu season. Afluria is manufactured by CSL Biotherapies, whose parent company operates one of the world’s largest influenza manufacturing facilities supply global markets.
Fluzone contains three inactivated (killed) influenza viruses: type A (H1N1), type A (H3N2) and type B. This vaccine is a split virus vaccine, which is generally associated with fewer adverse reactions in children. It is available in both pediatric and adult formulations, with no thimerosal as a preservative in prefilled syringes and with thimerosal as a preservative in multi-dose vials. Fluzone is manufactured by Sanofi Pasteur.
Fluvirin influenza vaccine is a leading product in the United States, and is approved for sale in more than 20 countries. It is an inactivated influenza virus vaccine indicated for persons four years of age and older against influenza caused by influenza virus subtypes A and type B contained in the vaccine. It is available in prefilled syringes and multi-dose vials. Fluvirin is manufactured by Novartis Vaccines.
Influenza vaccination is the most effective way to prevent influenza. Although the flu season can begin earlier and last longer, it usually starts in December, peaks in January or February, and continues through March. According to the U.S. Centers for Disease Control and Prevention (CDC), while October and November are traditionally the primary vaccination months, vaccination in December or later is still recommended for those who are not vaccinated earlier. Influenza vaccination not only helps decrease the risk of influenza and its complications for the vaccine recipient, but can also reduce the risk of the virus spreading to those who come in contact with vaccinated people.
Influenza has been in the news a lot, and many people are taking the threat of an H1N1 pandemic seriously. But, it’s important to remember that the annual seasonal flu kills more than 36,000 people each year in the United States alone. For most people, getting immunized against influenza is the easiest and most effective way to reduce their risk of infection. With annual vaccination, they can help protect themselves and avoid spreading infection to those who are unable to receive the vaccine.
FFF Enterprises, Inc
Article Directory: http://www.articledashboard.com
0 komentar